Century Therapeutics unveils plans to expand CNTY-101 clinical development into additional autoimmune diseases, including syste...

Needham analyst Gil Blum reiterates Nkarta (NASDAQ:NKTX) with a Buy and maintains $15 price target.

Canaccord Genuity analyst Bill Maughan maintains Nkarta (NASDAQ:NKTX) with a Buy and raises the price target from $15 to $16.

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning higher on Monday. The Dow traded down 0....

Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.

HC Wainwright & Co. analyst Emily Bodnar maintains Nkarta (NASDAQ:NKTX) with a Buy and raises the price target from $20 ...

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Monday. The Dow trad...